Effect of SAR302503 on ECG Activity in Patients With Solid Tumors

NCT01836705 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm Malignant

Interventions

DRUG: SAR302503 (TG101348)
DRUG: Placebo SAR302503
DRUG: Panolosetron

Sponsor

Bristol-Myers Squibb